• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

镓-PSMA-11 PET/MRI对生化复发前列腺癌的诊断性能：一项系统评价和荟萃分析。

The Diagnostic Performance of Ga-PSMA-11 PET/MRI for the Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-analysis.

作者信息

Wang Dan, Wang Zong-Hao, Wang Chun-Bao, Wu Zhi-Chun

机构信息

School of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, China.

出版信息

Iran J Public Health. 2024 Jun;53(6):1224-1235.

PMID:39430138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11488562/
Abstract

BACKGROUND

Our meta-analysis aimed to evaluate the diagnostic performance of Ga-PSMA-11 PET/MRI for biochemical recurrence of prostate cancer.

METHODS

We systematically and comprehensively searched all available studies until May 2023 in the PubMed and Embase databases. Studies evaluating Ga-PSMA-11 PET/MRI in men with prostate cancer biochemical recurrence were included. We appraised the quality of studies using a tailored Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. For each meta-analysis, we used the DerSimonian and Laird method. We first transformed proportions with the Freeman-Tukey double arcsine transformation, and then confidence intervals were calculated using the Jackson method. Meta-regression and sensitivity analysis were conducted to explore heterogeneity sources. Furthermore, we conducted subgroup analysis according to the PSA levels.

RESULTS

Overall, 13 studies with 738 patients were included in the analysis. The pooled overall detection rates of Ga-PSMA-11 PET/MRI in detecting recurrent PCa after definitive treatment were 74% (95% CI, 68%-79%). For patients with PSA under 0.5 ng/mL, the detection rate was 55 %. The detection rates were 79 %, 76 % and 87 % for the subgroup PSA levels of 0.5-0.99, 1.0-1.99 and over 2.0 ng/mL.

CONCLUSION

Ga-PSMA-11 PET/MRI has a good detection rate for biochemical recurrence of prostate cancer. However, large sample, multi-center studies are still needed to verify and expand on our conclusion.

摘要

背景

我们的荟萃分析旨在评估镓-PSMA-11 PET/MRI对前列腺癌生化复发的诊断性能。

方法

我们系统全面地检索了截至2023年5月在PubMed和Embase数据库中所有可用的研究。纳入评估镓-PSMA-11 PET/MRI在前列腺癌生化复发男性中的研究。我们使用定制的诊断准确性研究质量评估-2（QUADAS-2）工具评估研究质量。对于每项荟萃分析，我们采用DerSimonian和Laird方法。我们首先使用Freeman-Tukey双反正弦变换对比例进行转换，然后使用Jackson方法计算置信区间。进行荟萃回归和敏感性分析以探索异质性来源。此外，我们根据PSA水平进行亚组分析。

结果

总体而言，分析纳入了13项研究共738例患者。镓-PSMA-11 PET/MRI在检测根治性治疗后复发性前列腺癌的总体合并检出率为74%（95%CI，68%-79%）。对于PSA低于0.5 ng/mL的患者，检出率为55%。PSA水平为0.5-0.99、1.0-1.99和超过2.0 ng/mL的亚组检出率分别为79%、76%和87%。

结论

镓-PSMA-11 PET/MRI对前列腺癌生化复发具有良好的检出率。然而，仍需要大样本、多中心研究来验证和扩展我们的结论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/8c5b5184f3b3/IJPH-53-1224-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/6436c95c5d97/IJPH-53-1224-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/8efd68996b26/IJPH-53-1224-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/991652e8af95/IJPH-53-1224-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/b8ec85b378b0/IJPH-53-1224-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/8c5b5184f3b3/IJPH-53-1224-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/6436c95c5d97/IJPH-53-1224-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/8efd68996b26/IJPH-53-1224-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/991652e8af95/IJPH-53-1224-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/b8ec85b378b0/IJPH-53-1224-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c18/11488562/8c5b5184f3b3/IJPH-53-1224-g005.jpg

相似文献

1
The Diagnostic Performance of Ga-PSMA-11 PET/MRI for the Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-analysis.镓-PSMA-11 PET/MRI对生化复发前列腺癌的诊断性能：一项系统评价和荟萃分析。
Iran J Public Health. 2024 Jun;53(6):1224-1235.
2
Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: A meta-analysis.镓-PSMA PET/MRI 用于原发性和生化复发前列腺癌的诊断：一项荟萃分析。
Eur J Radiol. 2020 Sep;130:109131. doi: 10.1016/j.ejrad.2020.109131. Epub 2020 Jun 20.
3
Ga-PSMA-11 PET/CT versus Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis.镓-PSMA-11 PET/CT与镓-PSMA-11 PET/MRI用于检测生化复发前列腺癌的系统评价和荟萃分析
Front Oncol. 2023 Aug 14;13:1216894. doi: 10.3389/fonc.2023.1216894. eCollection 2023.
4
Recurrent prostate cancer: combined role for MRI and PSMA-PET in Ga-PSMA-11 PET/MRI.复发性前列腺癌：MRI 和 PSMA-PET 在 Ga-PSMA-11 PET/MRI 中的联合作用。
Eur Radiol. 2024 Jul;34(7):4789-4800. doi: 10.1007/s00330-023-10442-4. Epub 2023 Dec 1.
5
Head-to-head comparison of Ga-PSMA-11 PET/CT and Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies.镓-PSMA-11 PET/CT与镓-PSMA-11 PET/MRI在前列腺癌生化复发检测中的头对头比较：头对头比较研究综述
Prostate Cancer Prostatic Dis. 2023 Mar;26(1):16-24. doi: 10.1038/s41391-022-00581-y. Epub 2022 Aug 5.
6
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用：系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
7
Detection Rate of PSMA PET Using Different Ligands in Men with Biochemical Recurrent Prostate Cancer Following Radical Treatment: A Systematic Review and Meta-analysis of Prospective Studies.根治性治疗后生化复发前列腺癌男性患者中使用不同配体的PSMA PET检测率：前瞻性研究的系统评价和荟萃分析
Acad Radiol. 2024 Feb;31(2):544-563. doi: 10.1016/j.acra.2023.08.044. Epub 2023 Sep 27.
8
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
9
Sensitivity, Specificity, and Predictors of Positive Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis.前列腺特异性膜抗原正电子发射断层扫描在晚期前列腺癌中的敏感性、特异性和阳性预测值：系统评价和荟萃分析。
Eur Urol. 2016 Dec;70(6):926-937. doi: 10.1016/j.eururo.2016.06.021. Epub 2016 Jun 28.
10
Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.镓-PSMA-11 PET/CT 在复发性前列腺癌中的应用：根治性治疗后 PSA 失败不同临床阶段的疗效。
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

引用本文的文献

1
Surveillance After Focal Therapy for Prostate Cancer: A Comprehensive Review.前列腺癌局部治疗后的监测：全面综述
Cancers (Basel). 2025 Apr 16;17(8):1337. doi: 10.3390/cancers17081337.

本文引用的文献

1
Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3.前列腺癌的年龄相关前列腺特异性抗原检测：英国国家卫生与临床优化研究所建议1.6.3。
BJU Int. 2023 Jan;131(1):130-131. doi: 10.1111/bju.15859. Epub 2022 Dec 5.
2
Urinary exosomal prostate-specific antigen is a noninvasive biomarker to detect prostate cancer: Not only old wine in new bottles.尿外泌体前列腺特异性抗原是一种非侵入性的生物标志物，可用于检测前列腺癌：并非陈酒换新瓶。
Int J Cancer. 2023 Apr 15;152(8):1719-1727. doi: 10.1002/ijc.34388. Epub 2022 Dec 12.
3
Ga-PSMA PET/CT in early relapsed prostate cancer patients after radical therapy.
镓-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在根治性治疗后早期复发前列腺癌患者中的应用
Sci Rep. 2022 Nov 28;12(1):20500. doi: 10.1038/s41598-022-24688-3.
4
Positive Prostate-specific Membrane Antigen Findings: How To Interpret Them.前列腺特异性膜抗原阳性结果：如何解读它们。
Eur Urol Oncol. 2023 Apr;6(2):113-115. doi: 10.1016/j.euo.2022.10.007. Epub 2022 Nov 22.
5
The Gene Expression Landscape of Prostate Cancer BM Reveals Close Interaction with the Bone Microenvironment.前列腺癌 BM 的基因表达谱揭示了与骨微环境的密切相互作用。
Int J Mol Sci. 2022 Oct 27;23(21):13029. doi: 10.3390/ijms232113029.
6
How can we best manage biochemical failure after radical prostatectomy?根治性前列腺切除术后如何最好地管理生化失败？
Investig Clin Urol. 2022 Nov;63(6):592-601. doi: 10.4111/icu.20220294.
7
Molecular Genetics of Prostate Cancer and Role of Genomic Testing.前列腺癌的分子遗传学与基因组检测的作用。
Surg Pathol Clin. 2022 Dec;15(4):617-628. doi: 10.1016/j.path.2022.08.002. Epub 2022 Oct 13.
8
Assessing extra-prostatic extension for surgical guidance in prostate cancer: Comparing two PSMA-PET tracers with the standard-of-care.评估前列腺癌手术指导中的前列腺外扩展：将两种PSMA-PET示踪剂与护理标准进行比较。
Urol Oncol. 2023 Jan;41(1):48.e1-48.e9. doi: 10.1016/j.urolonc.2022.10.003. Epub 2022 Nov 1.
9
Managing the impact of inter-method bias of prostate specific antigen assays on biopsy referral: the key to move towards precision health in prostate cancer management.管理前列腺特异性抗原检测方法间偏倚对活检转诊的影响：实现前列腺癌管理精准医学的关键。
Clin Chem Lab Med. 2022 Nov 2;61(1):142-153. doi: 10.1515/cclm-2022-0874. Print 2023 Jan 27.
10
Drivers of Radioresistance in Prostate Cancer.前列腺癌放射抗性的驱动因素
J Clin Med. 2022 Sep 24;11(19):5637. doi: 10.3390/jcm11195637.